

## Reactions of Methylene-cyclopropanes with a Diethylzinc-Bromoform System, and the Utilization for Synthesis of a Novel Cyclopropylidene-Nucleoside

Changmei Cheng, Tetsuro Shimo, Kenichi Somekawa\* and Masaru Kawaminami†


\* Department of Applied Chemistry and Chemical Engineering, Faculty of Engineering, Kagoshima University, Korimoto, Kagoshima 890 Japan

† Department of Physics, Faculty of Science, Kagoshima University, Korimoto, Kagoshima 890 Japan

**Abstract:** The reactions of substituted methylenecyclopropane with diethylzinc-bromoform gave bromospiro[2.2]pentane derivatives, bromoform-addition compounds, an oxabicyclo-compound and adjacent dibromo-compound, and the last product was derived to a novel  $\alpha$ ,  $\beta$ -unsaturated nucleoside.


© 1997 Elsevier Science Ltd.

Carbocyclic oxetanocins<sup>1</sup> and allene-nucleosides<sup>2</sup> are effective for HIV and other viruses, but cyclopropyl- and cyclopropylmethyl-nucleosides<sup>3</sup> are ineffective. For study of the structure-activity relationships and in new drug design, syntheses of novel cyclopropylidene and/or spiro[2.2]pentyl-nucleosides are considered to be of prime importance.



Akhachinskaya showed stereoselective additions of dihalocarbenes to 2-substituted methylenecyclopropanes to give dihalospiro[2.2]pentane derivatives.<sup>4</sup> Miyano et al. also reported monobromocyclopropanation reactions between simple olefins and a bromocarbene intermediate which was generated from a diethylzinc bromoform system.<sup>5</sup> In the course of our work to synthesize novel carbocyclic nucleosides, we first examined some reactions of substituted methylenecyclopropanes 1, 2, 3, 4 with a diethylzinc-bromoform system to prepare the key intermediates of substituted bromospiro[2.2]pentanes and dibromocyclopropanes as shown in Scheme 1 and Table 1.

Thus, the reaction of dimethyl 3-methylene-cyclopropane-trans-1, 2-dicarboxylate 1 (Feist's diester)<sup>6</sup>-CHBr<sub>3</sub>-Et<sub>2</sub>Zn system (1:7:6) was carried out at 68°C in nitrogen atmosphere to afford the target molecule, dimethyl 4-bromospiro[2.2]



pentane-trans-1, 2-dicarboxylate 5<sup>7</sup>, in 12% yield after column chromatography(1:5 ethyl acetate/hexane), and the isomer ratio was 8:3 (by <sup>1</sup>H NMR spectrum). A similar mixture was then reacted in air atmosphere which was reported to have accelerated generation of the bromocarbene reagent from diethylzinc and bromoform.<sup>5</sup> At the low temperature, the reaction did not give the target molecule, upon heating the reaction mixture to 68°C, we obtained unexpectedly, dimethyl 3-bromo-3-(2, 2-dibromoethyl)cyclopropane-trans-1,2-dicarboxylate 6<sup>8</sup> in

61% yield. **6** may be a radical-fission adduct of bromoform to **1**. Changing of the solvents, molecular ratio and catalysts gave no better result for the spiro-compound.











Carbenes or carbenoids usually act as electrophilic reagents when they are added to olefins, so it is reasonable for the yield of the spiro-compound to be low as **1** has two electron-withdrawing groups in the three-membered ring. In order to increase electron density of the double bond on the substrates, compound **1** was reduced by LiAlH<sub>4</sub> to give Feist's diol<sup>9</sup>, and the diol was derived to the corresponding TMS and TBDMS ethers **2**<sup>10</sup> and benzyl ether **3**.<sup>11</sup>

Compound **2** was consumed but gave no meaningful products under several conditions. On the other hand, the same treatment of compound **3** at 68°C gave 6-benzyloxymethyl-1-bromo-3-oxabicyclo[3.1.0]hexane **7**<sup>12</sup> and 1-bromo-1-bromomethyl-trans-2,3-di(benzyloxymethyl)cyclopropane **8**<sup>13</sup> in 15% and 12% yields, respectively, after column chromatography (1:10 ethyl acetate/hexane). These results suggest the existence of some radical competing reactions. Compound **2** might be charged with radical fission at the electron-rich silylether bonds.


Compound **4** was subjected to the reaction at 60°C to give the target molecule, ethyl 4-bromospiro[2.2]pentane-1-carboxylate **9**<sup>14</sup>, in 46% yield, whose isomer ratio was 2:1, in addition to ethyl 2-bromo-2-(2,2-dibromomethyl)cyclopropane-1-carboxylate **10**<sup>15</sup> (8% yield). The whole reaction mechanism is inferred as shown in Scheme 2 and it agrees with Miyano's inference.<sup>5</sup>

Compounds **5**, **8**, **9** were subjected to coupling with adenine in the presence of K<sub>2</sub>CO<sub>3</sub>, and only **8** afforded a cyclopropylidenemethylenyladenine **11**<sup>16</sup> in 65% yield. The structure of crystal **11** was confirmed as Figure 1 by X-ray analysis. **11** was deprotected by 6 eq. BCl<sub>3</sub> at -20°C to give a novel α, β-

Table 1. Reactions of Substituted Methylenecyclopropanes-Diethylzinc-Bromoform Systems and the Products

Starting Materials	Products and Yields	
		
<b>1</b>	<b>5</b> 12%	<b>6</b> 61%
	No products were isolated	
<b>2</b>		
		
<b>3</b>	<b>7</b> 15%	<b>8</b> 12%
		
<b>4</b>	<b>9</b> 46%	<b>10</b> 8%

R<sup>3</sup>: TMS, TBDMS



Scheme 2

**8** afforded a cyclopropylidenemethylenyladenine **11**<sup>16</sup> in 65% yield. The structure of crystal **11** was confirmed as Figure 1 by X-ray analysis. **11** was deprotected by 6 eq. BCl<sub>3</sub> at -20°C to give a novel α, β-

unsaturated nucleoside, trans-3',4'-di(hydroxymethyl)cyclopropylidenemethylenyladenine **12**<sup>17</sup>, in 91% yield as shown in Scheme 3.





Figure 1, Molecular structure of **11** crystal



Scheme 3

Other trials of coupling reactions between spiro-compounds, etc. and bases, and the interesting anti-HIV-1 activity data of the cyclopropylidene nucleosides will be reported in our next paper.

#### References and notes

1. Nishiyama, Y.; Yamamoto, N.; Yamada, Y.; Ichikawa, Y.; Takahashi, K., *J. Antibiot.*, **1989**, *12*, 5925.
2. Phadtare, S.; Zemlicka, J. *J. Am. Chem. Soc.* **1989**, *111*, 5925.
3. Katagiri, N. *Yakugaku Zasshi*, **1993**, *113*, 285.
4. Akhachinskaya, I. V.; Donskaya, N. A. Kalyakina, I. V.; Oprunenko, Y. F.; Shabarov, Y. S. *Zh. Org. Khim.* **1989**, *25*, 1645.
5. Miyano, S.; Hashimoto, H. *Bull. Chem. Soc. Jpn.*, **1975**, *48*, 3665.
6. Blomquist, A. T.; Longone, D. T. *J. Am. Chem. Soc.*, **1959**, *81*, 2012.
7. All new compounds gave satisfactory spectral data. **5a**: <sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>) δ:3.74(s, 6H), 3.36(dd, 1H, J=4.4Hz, 7.6Hz), 2.80(d, 1H, J=4.0Hz), 2.65(d, 1H, J=4.0Hz), 1.86(t, 1H, J=7.6Hz), 1.45(dd, 1H, J=4.4Hz, 7.6Hz); <sup>13</sup>C NMR(100MHz, CDCl<sub>3</sub>) δ:52.64, 52.56, 30.45, 28.99, 28.65, 20.14, 16.56, 170.53, 170.35; MS(m/z): 262 M<sup>+</sup>, 264 (M+2)<sup>+</sup>. **5b**: <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>) δ:3.70(s, 6H), 3.50 (dd, 1H, J=4.4Hz, 7.6Hz), 2.87(d, 1H, J=4.0Hz), 2.74(d, 1H, J=4.0Hz), 1.65(t, 1H, J=7.6Hz), 1.59(dd, 1H, J=4.4Hz, 7.6Hz); <sup>13</sup>C NMR(100MHz, CDCl<sub>3</sub>) δ:169.12, 167.52, 52.39, 52.31, 30.96, 28.20, 20.41, 19.73, 14.11; MS(m/z): 262 M<sup>+</sup>, 264 (M+2)<sup>+</sup>.
8. **6**: <sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>) δ:6.00(t, 1H, J=7.2Hz), 3.81(s, 6H), 3.11(ddd, 2H, J=7.2Hz, 7.2Hz,

- 14.0Hz), 2.87(d, 1H, J=7.2Hz), 2.65(d, 1H, J=7.2Hz);  $^{13}\text{C}$  NMR(100MHz,  $\text{CDCl}_3$ ) $\delta$ : 168.52, 166.93, 52.84, 52.81, 48.35, 41.71, 39.37, 33.77, 33.37; MS(m/z): 389 (M-CH<sub>3</sub>O)<sup>+</sup>, 391 (M+2-CH<sub>3</sub>O)<sup>+</sup>, 393 (M+4-CH<sub>3</sub>O)<sup>+</sup>, 395 (M+6-CH<sub>3</sub>O)<sup>+</sup>.
9. Gajewski, J. J. *J. Am. Chem. Soc.*, **1971**, 93, 4450.
10. Norbeck, D. W.; Sham, H. L.; Herrin, T.; Rosenbrook, W.; Plattner, J. J. *J. Chem. Soc., Chem. Commun.*, **1992**, 128.
11. Hsiao, C. N.; Hannick, S. M. *Tetrahedron Lett.*, **1990**, 31, 6609.
12. **7**:  $^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.33(m, 5H), 4.56(s, 2H), 4.08(d, 1H, J=8.0Hz), 3.88(dd, 1H, J=8.0Hz, 3.2Hz), 3.85(d, 1H, J=8.6Hz), 3.78(d, 1H, J=8.6Hz), 3.65(d, 2H, J=7.2Hz), 1.71(dd, 1H, J=3.2Hz, 4.8Hz), 1.41(dt, 1H, J=4.8Hz, 7.2Hz);  $^{13}\text{C}$  NMR(100MHz,  $\text{CDCl}_3$ )  $\delta$ : 138.45, 130.00, 128.73, (2C), 128.03(2C), 75.70, 73.33, 70.83, 69.49, 38.75, 30.45, 24.86; MS(m/z): 282 (M)<sup>+</sup>, 284 (M+2)<sup>+</sup>
13. **8**:  $^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.31(m, 10H), 4.57(q, 2H, J=11.6Hz), 4.50(q, 2H, J=11.6Hz), 3.86(q, 2H, J=11.6Hz), 3.70(m, 4H), 1.76(dd, 1H, J=7.2Hz, 12.6Hz), 1.35(dd, 1H, J=7.2Hz, 12.6Hz); MS(m/z): 360 (M-C<sub>7</sub>H<sub>8</sub>)<sup>+</sup>, 362 (M+2-C<sub>7</sub>H<sub>8</sub>)<sup>+</sup>, 364 (M+4-C<sub>7</sub>H<sub>8</sub>)<sup>+</sup>. **8** also was quantitatively obtained by bromination of **3**.
14. **9a**:  $^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ )  $\delta$ : 4.13(ddq, 2H, J=8.8Hz, 8.8Hz, 14.0Hz), 3.33(dd, 1H, J=4.0Hz, 2.8Hz), 2.21(dd, 1H, J=8.0Hz, 5.2Hz), 1.70(dd, 1H, J=6.8Hz, 4.0Hz), 1.59(dd, 1H, J=8.0Hz, 5.2Hz), 1.52(dd, 1H, J=8.0Hz, 5.2Hz), 1.38(dd, 1H, J=6.8Hz, 2.8Hz), 1.25(t, 3H, J=8.8Hz); MS(m/z): 218 M<sup>+</sup>, 220 (M+2)<sup>+</sup>. **9b**:  $^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ )  $\delta$ : 4.15(ddq, 2H, J=8.8Hz, 8.8Hz, 14.0Hz), 3.45(dd, 1H, J=4.4Hz, 6.8Hz), 2.21(dd, 1H, J=8.4Hz, 4.8Hz), 1.83(t, 1H, J=4.8Hz), 1.68(t, 1H, J=7.2Hz), 1.60(dd, 1H, J=8.4Hz, 4.8Hz), 1.43(dd, 1H, J=7.2Hz, 4.4Hz), 1.25(t, 3H, J=8.8Hz); MS(m/z): 218 M<sup>+</sup>, 220 (M+2)<sup>+</sup>.
15. **10**:  $^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ )  $\delta$ : 5.98(t, 1H, J=7.2Hz), 4.18(ddq, 2H, J=7.2Hz, 7.2Hz, 14.4Hz), 3.06(ddd, 2H, J=7.2Hz, 7.2Hz, 14.0Hz), 2.36(t, 1H, J=8.4Hz), 1.71(ddd, 2H, J=8.4Hz, 8.4Hz, 10.8Hz), 1.28(t, 3H, J=7.2Hz);  $^{13}\text{C}$  NMR (100MHz,  $\text{CDCl}_3$ )  $\delta$ : 164.56, 61.50, 47.87, 42.97, 37.20, 29.02, 23.54, 14.23; MS(m/z): 375 M<sup>+</sup>, 377 (M+2)<sup>+</sup>, 379 (M+4)<sup>+</sup>, 381 (M+6)<sup>+</sup>.
16. **11**:  $^1\text{H}$  NMR(400MHz,  $\text{CDCl}_3$ )  $\delta$ : 8.79(s, 1H), 8.37(s, 1H), 7.58(t, 1H, J=2.0Hz), 7.30(m, 10H), 4.56(m, 4H), 3.88(dd, 1H, J=9.6Hz, 5.6Hz), 3.62(dd, 1H, J=10.4Hz, 6.0Hz), 3.42(dd, 1H, J=10.4Hz, 7.6Hz), 3.33(t, 1H, J=9.6Hz), 2.07(dddd, 1H, J=9.6Hz, 5.6Hz, 5.0Hz, 2.0Hz), 1.94(dddd, 1H, J=7.6Hz, 6.0Hz, 5.0Hz, 2.0Hz);  $^{13}\text{C}$  NMR(100MHz,  $\text{CDCl}_3$ )  $\delta$ : 155.34, 153.21, 149.00, 138.53, 138.06, 137.68, 128.53(2C), 128.48(2C), 128.40, 127.86(2C), 127.78(2C), 127.73, 119.00, 116.59, 112.03, 73.20, 72.82, 71.39, 71.15, 22.99, 20.08; Anal. calcd for C<sub>25</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub> C 70.26, H 5.85, N 16.39, found C 69.92, H 5.85, N 16.09; MS(m/z): 427 M<sup>+</sup>. The X-ray data of **11** will be fully presented in our other paper.
17. **12**:  $^1\text{H}$  NMR(400MHz, CD<sub>3</sub>OD)  $\delta$ : 8.86(s, 1H), 8.42(s, 1H), 7.58(t, 1H, J=2.0Hz), 3.84(dd, 1H, J=12.0Hz, 6.8Hz), 3.62(d, 2H, J=6.8Hz), 3.56(dd, 1H, J=12.0Hz, 6.8Hz), 2.14(ddt, 1H, J=6.8Hz, 5.0Hz, 2.0Hz), 2.00(ddt, 1H, J=6.8Hz, 5.0Hz, 2.0Hz);  $^{13}\text{C}$  NMR(100MHz, CD<sub>3</sub>OD)  $\delta$ : 151.98, 148.92, 146.50, 143.18, 123.78, 119.73, 112.42, 64.17, 64.00, 26.37, 23.87; MS(m/z): 247 M<sup>+</sup>; HRMS calcd for C<sub>11</sub>H<sub>13</sub>N<sub>5</sub>O<sub>2</sub> 247.1071, found 247.1111.